Category: news

PHILADELPHIA--(BUSINESS WIRE) -- Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-031, a recombinant adeno-associated virus (rAAV) based gene therapy that is being studied for the treatment of neovascular Age Related Macular Degeneration (nAMD), the leading cause of severe vision loss and irreversible blindness worldwide. Read full press release

PHILADELPHIA, PA, September 15, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the appointment of Mahen Gundecha as Chief Business Officer. Read full press release

PHILADELPHIA, PA, Sep 8, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the next phase of its business expansion, including plans to double in size during the next 12 months and opening of business offices in Philadelphia, research operations in Boston and a regional office in Singapore. Read full press release

PHILADELPHIA, PA, June 23, 2021 (BUSINESS WIRE) – Exegenesis Bio, a rapidly growing global gene therapy company, developing innovative genetic medicines for eye, CNS and liver-directed diseases is pleased to announce the completion of its series B++ financing, raising over $50 M of venture investments in this round. The round was led by Hillhouse Capital Group and included existing investors LYFE Capital and BioTrack Capital, as well as new investors Temasek Holdings, CPE and Lake Bleu Capital. Read full press release